Ingestible Electronically Controlled Drug Capsule is the targeted delivery of drug in the Gut. It cons ists of an ingestible capsule consist ing of a pH s ens or w hich releas e drug in a particular pH, thermos ensors which monitor temperature of body, battery which provide cont inuous power supply to the capsule, F luid Pump, Drug Res ervoir and Dispens ing hole. By the help of gut pH, press ure and t emp erature a wireless mot ility capsule has been est ablished. It has been constructed to be engulfed and didn't int erfere the nat ural human digestive system 1 . The s cheme compris es of a digestible ant enna and microchip to a normal-s ize shell. When we ingest the pill then it starting w orking by producing the s ignals which is receiving by a small electronic device supported by the patient. This device is linked w ith laptop, cell phone or computer, ale rting doctors and family member 2 .
IN TROD UCTION
Ingestible Electronically Controlled Drug Capsule is the targeted delivery of drug in the Gut. It cons ists of an ingestible capsule consist ing of a pH s ens or w hich releas e drug in a particular pH, thermos ensors which monitor temperature of body, battery which provide cont inuous power supply to the capsule, F luid Pump, Drug Res ervoir and Dispens ing hole. By the help of gut pH, press ure and t emp erature a wireless mot ility capsule has been est ablished. It has been constructed to be engulfed and didn't int erfere the nat ural human digestive system 1 . The s cheme compris es of a digestible ant enna and microchip to a normal-s ize shell. When we ingest the pill then it starting w orking by producing the s ignals which is receiving by a small electronic device supported by the patient. This device is linked w ith laptop, cell phone or computer, ale rting doctors and family member 2 .
Advantages of e-Capsule:
It has potentials to be a valuable research tool for the develop ment of any new drug that is deliver ed through int estinal tract. With help of this device the locat ion in the gut can b e det ermined w ith good accuracy 3 . It has been developed to meas ure trans it time 4 . It will help effort lessly to attain dat a on the intest inal absorption of a drug in humans. It w ill help to communicate t he patient with the P hysician and the Pharmacist through mobile or laptop. It is us ed to locally treat a medical condition.
Problem S tate ment
The problem with administ ering numerous medications orally is that a pill oft en w ill not dissolve at precis ely the right site in the gastrointest inal tract where the medicine can be abs orbed into the bloodstream 5
LITERATURE REVIEW

Ph ysical delive ry of Pharmaceu tical agen t:
Zdeblick M ark and his co-w orker have developed Composit ions, systems and met hods that suggested the ident ification of the act ual physical delivery of a pharmaceut ical agent to a body. It includes an ident ifier and an active agent. The innovator finds use in a variety of different applications such as monitoring of therapeutic regimen compliance and tracking the history of pharmaceut ical agent 6 .
Analyte monitoring an d dru g deli very system:
Holmes Elizabet h and his co -worker have w ork on the analyte monitoring and drug delivery system. The innovat ion narrates to an ingestible, implantable or w earable medical device cons isting of a microarray which encompass es a bioact ive agent able of int eract ing w ith a diseas e marker biological analyte. M echanis m includes a res ervoir that cont ains with minimum one therap eutic mediator and has the capacity of releas ing the t herap eutic mediator from the medical gadgets and numerous microchips consist ing of a microarray scanning instrument that have the ability of analysing the physical paramet er data of a communication between the dis eas e marker biological analyte with the bioactive agent. It also contains a biometric recognition device proficient of linking t he physical paramet er dat a w ith an analyte int eract ion profile; an out er surface gadget capable of helping int eract ion betw een the biometric recognition device, microarray s canning device, and t he therapeutic agent ; and a power s ource to control the medical gadgets 7 .
Re mote Controlled C apsule:
Remot e Controlled Capsule (RCC) is a new t echnique to underst and non-invas ive drug delivery to the specific locations of human gut. Human Drug A bsorption (HDA) studies are t aken effort lessly to attain data on the int estinal absorption of a drug in humans. This system has been prearranged using M EM S technology to make available for the delivery of a n ext ens ive choice of different drug formulations . A magnetic M arker M onitoring (M MM ) system w as est ablished to monit or t he place of the capsule inside the gut. A new method to indicate the drug releas e, called as Indicat ing System built on A brupt M ovement of M arker (ISAM M ), was proposed in this study. It has been proved by animal models 8 . 
Magnetic marke r monitoring:
A patent ed remote contro lled capsule (RCC) has newly been des ign to provide noninvas ive drug delivery to cert ain sit es in the human gut that allows ass essment of local gastroint estinal (GI) drug abs orption under a normal physiological environment. For this purpos e rate and ext ent of aminophylline absorption aft er s ite-sp ecific delivery of the drug in the GI tract has been studied using RCC and a magnetic marker monitoring (M MM ) technique. After this study it was found that the propriet ary of the RCC and M MM technique offer the chance to gain dat a on the intestinal absorption of a drug in humans under noninvas ive conditions. A minophylline is quickly and w ell absorbed from the s mall bow el. While colonic abs orption w as restricted by the poor water condit ion alt hough effective abs orption was obs erved from the ascending colon. This offers a chance for rat ional development of modified-releas e formulations as w ell as alternative do sage forms 9 .
In telligent Pill:
After the approval of the first camera pill by Federal Drug Administration in 2 001 for diagnost ic purpos es, many res earchers are then working to des ign such pill that also have the capability to deliver the drug. Aft er s even years the efforts succeed and a renowned organizat ion has developed an int elligent pill w hich can be electroni cally programmed to control the drug delivery to a pre-defined rat e in the Gut. It can be monitor eas ily and also ident ified its location by attaching different s ensors such as t emperature sensor and pH s ens ors which is used to track the drug and als o aid when to release the drug in the G ut. The iP ill discharges medicine from its drug res ervoir through microprocessor scaled pump, letting accurate programmable drug delivery. It als o have the ability to measure the t emp erature and pH 10 .
.
Fig ure 2 : iPill
Magnetic Pill S ystem:
Brow n Univers ity researchers are working w ith the problem that orally administ ered drug w ill never diss olved at appropriate s ite in the Gut. They succeeded to s olve this problem by developing a new magnet ic p ill system. T his has opened a big horiz on in the field of res earch. The system comprises of gelatin capsules along w ith a t iny magnet and an ext ernal magnet t hat can precis ely sens e the force between them. The pill deviat e that force where needed to grip the pill in place. The ext erior magnets can intellect the pill's pos ition. To avoid any injury to nearby tissue we have to monit or the force that are applying through external magnet . To avoid this Bryan Laulicht took careful dimensions and made an ext ernal magnet structure w ith sens itive computer regu lator and feedback mechanisms 11 .
In gesti ble e vent marker (IEM) s ystem:
An Ingest ible event marker (IEM ) system is des ign by an organiz ation that covers a personal s ignal receiver and an ingest ible event marker. It is act ivated upon cont act w ith a target int erior physiological s ite of a body like digestive tract int ernal target s ite. The personal s ignal receiver is aimed to be related with a physiological location s uch as ins ide of or on the body and to receive a s ignal through IEM . The IEM programmes a s ignal which is received by the personal s ignal receiver 12 . An ingestible therapy activator system and method are one aspect of the ingestible therapy act ivator t hat includes an ingestible device having an effector module to send an effector inst ruction and a responder module relat ed w ith a therapeutic device. The responder module may receive and process the effector instruct ion, res ult ing in a respons e by the therapeutic device such as therapeut ic device includ e act ivating a therapy, deact ivat ing a therapy, modulat ing a therapy, and dis continuing a therapy 13 . Ingest ible event markers having high reliability are provided. Asp ects of the ingest ible event markers compris e a support, a control circuit, a first elect rochemical mat erial, a second electrochemical material and a membrane. In addit ion, the ingest ible event markers might compris e one or more components that impart high reliability to the ingestible event marker. Furt her, the ingestible event markers may co ntain an act ive agent. In some asp ects , the active agent, s uch as a pharmaceut ically active agent or a diagnostic agent may be associat ed w ith the membrane 14 .
A Miniaturize d Ele ctroni c De vi ce:
A miniaturized in -body electronic device is provided containing one or more ant ennas may be galvanically joined to receive an alt ernat ing current (AC) s ignal through the body of a subject where the in-body electronic device is located. Pow er extraction circuitry is configured to ext ract electrical power from the AC signal received by the ant enna. The extracted electrical power is used for electrically powering one or more components of the electronic device. A transmitter is coup led to receive power from the power ext ract ion circuitry. A controller is coupled to the transmitter. The controller is configured to activate the trans mitter to generat e a sequence of intermittent trans mission bursts for trans mitting an uplink signal; a t rans miss ion burst may have a higher instant aneous pow er level than an inst ant aneous power level of the A C signal received by the ant enna 15 .
Teppe r Robert an d his co -workers:
Tepper Robert and his co -workers des cribe a devices, systems, and kits for delivering s ubst ances to t issues . The devices us ually include one or more chambers and a reservoi r w ithin each chamber. The reservoir may locally deliver a micro dose amount of a substance to a target tissue. In some variat ions, a micro dos e amount is us ed in early human studies , e.g., before a phas e I clinical trial, to evaluat e the effect of the subst ance on a target tissue, or to obt ain pharmacokinetic or met abolic dat a. In other variations , a micro dos e quantity is us ed to locally treat a medical condition. In yet other variat ions , a micro dos e amount is us ed t o locally deliver a cont rast agent for a struct ural or functional imaging procedure. M ethods for delivering and retrieving the devices from the t arget t issue are als o des cr ibed 16 .
Ele ctroni c C ontrol of Dru g Deli very S ystem:
Saad D avid and his co-w orker explain a drug delivery device for driving an electrotransport current through a body surface of a user is provided. The device cont ains a p atch w ith two electrodes and one or more reservoirs storing a t herap eutic agent. The one or more res ervoirs releas e the therapeut ic agent into the body surface of the us er when the res ervoirs are locat ed over the electrodes t o creat e an electrical path for the electrot ransport current. The device consists of a controller which regulates a controllable power supply to drive the electrot ransport current t hrough the body surface of the us er in a programmed profile 17 
DIS CUS S ION
Electronically drug delivery system will bring new horiz on in the t arget drug delivery system. It is beneficial to monitor the drug delivery in t he Gut and also helps to improve the therapeutically drug regimen. If the capsule is introduced in the blood t hrough microencapsulation then it w ill helps in the Physician and P harmacist to monit or the drug throughout the body compartment and it is used as res earch tools for clinical trials . The purpos ed structure for the electronically controlled drug capsule is as follows
